Oramed Pharmaceuticals Net Income
| ORMP Stock | USD 3.38 0.05 1.46% |
As of the 11th of February 2026, Oramed Pharmaceuticals holds the Semi Deviation of 1.98, coefficient of variation of 452.46, and Risk Adjusted Performance of 0.1847. Compared to fundamental indicators, the technical analysis model allows you to check existing technical drivers of Oramed Pharmaceuticals, as well as the relationship between them.
Oramed Pharmaceuticals Total Revenue |
|
Gross Profit | Profit Margin | Market Capitalization | Enterprise Value Revenue 1.3477 | Revenue |
| Last Reported | Projected for Next Year | ||
| Net Loss | -17.2 M | -16.3 M | |
| Net Loss | -22 M | -23.1 M | |
| Net Loss | (0.54) | (0.56) | |
| Net Income Per E B T | 1.08 | 0.71 |
Oramed | Net Income | Build AI portfolio with Oramed Stock |
Evaluating Oramed Pharmaceuticals's Net Income across multiple reporting periods reveals the company's ability to sustain growth and manage resources effectively. This longitudinal analysis highlights inflection points, cyclical patterns, and structural changes that short-term snapshots might miss, offering deeper insight into Oramed Pharmaceuticals's fundamental strength.
Latest Oramed Pharmaceuticals' Net Income Growth Pattern
Below is the plot of the Net Income of Oramed Pharmaceuticals over the last few years. Net income is one of the most important fundamental items in finance. It plays a large role in Oramed Pharmaceuticals financial statement analysis. It represents the amount of money remaining after all of Oramed Pharmaceuticals operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue. It is Oramed Pharmaceuticals' Net Loss historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Oramed Pharmaceuticals' overall financial position and show how it may be relating to other accounts over time.
| View | Last Reported (19.06 M) | 10 Years Trend |
|
Net Income |
| Timeline |
Oramed Net Income Regression Statistics
| Arithmetic Mean | (11,132,841) | |
| Geometric Mean | 7,067,306 | |
| Coefficient Of Variation | (90.34) | |
| Mean Deviation | 7,313,063 | |
| Median | (10,964,000) | |
| Standard Deviation | 10,057,147 | |
| Sample Variance | 101.1T | |
| Range | 43.3M | |
| R-Value | (0.57) | |
| Mean Square Error | 72.8T | |
| R-Squared | 0.33 | |
| Significance | 0.02 | |
| Slope | (1,136,546) | |
| Total Sum of Squares | 1618.3T |
Oramed Net Income History
Other Fundumenentals of Oramed Pharmaceuticals
Oramed Pharmaceuticals Net Income component correlations
Oramed Net Income Driver Correlations
Understanding the fundamental principles of building solid financial models for Oramed Pharmaceuticals is extremely important. It helps to project a fair market value of Oramed Stock properly, considering its historical fundamentals such as Net Income. Since Oramed Pharmaceuticals' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Oramed Pharmaceuticals' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Oramed Pharmaceuticals' interrelated accounts and indicators.
Click cells to compare fundamentals
Can Pharmaceuticals industry sustain growth momentum? Does Oramed have expansion opportunities? Factors like these will boost the valuation of Oramed Pharmaceuticals. Anticipated expansion of Oramed directly elevates investor willingness to pay premium valuations. Determining accurate worth demands scrutiny of both present operating results and projected expansion capacity. Evaluating Oramed Pharmaceuticals demands reviewing these metrics collectively while recognizing certain factors exert disproportionate influence.
Quarterly Earnings Growth 0.409 | Earnings Share 0.99 | Revenue Per Share | Quarterly Revenue Growth (1.00) | Return On Assets |
Oramed Pharmaceuticals's market price often diverges from its book value, the accounting figure shown on Oramed's balance sheet. Smart investors calculate Oramed Pharmaceuticals' intrinsic value - its true economic worth - which may differ significantly from both market price and book value. Market participants employ diverse analytical approaches to determine fair value and identify buying opportunities when prices dip below calculated worth. Since Oramed Pharmaceuticals' trading price responds to investor sentiment, macroeconomic conditions, and market psychology, it can swing far from fundamental value.
It's important to distinguish between Oramed Pharmaceuticals' intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Oramed Pharmaceuticals should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. However, Oramed Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Oramed Pharmaceuticals 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Oramed Pharmaceuticals' stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Oramed Pharmaceuticals.
| 11/13/2025 |
| 02/11/2026 |
If you would invest 0.00 in Oramed Pharmaceuticals on November 13, 2025 and sell it all today you would earn a total of 0.00 from holding Oramed Pharmaceuticals or generate 0.0% return on investment in Oramed Pharmaceuticals over 90 days. Oramed Pharmaceuticals is related to or competes with Ovid Therapeutics, Context Therapeutics, Clene, Shattuck Labs, Coya Therapeutics, MacroGenics, and ImageneBio. Oramed Pharmaceuticals Inc. engages in the research and development of pharmaceutical solutions for the treatment of dia... More
Oramed Pharmaceuticals Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Oramed Pharmaceuticals' stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Oramed Pharmaceuticals upside and downside potential and time the market with a certain degree of confidence.
| Downside Deviation | 2.67 | |||
| Information Ratio | 0.1952 | |||
| Maximum Drawdown | 17.67 | |||
| Value At Risk | (3.76) | |||
| Potential Upside | 6.98 |
Oramed Pharmaceuticals Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Oramed Pharmaceuticals' investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Oramed Pharmaceuticals' standard deviation. In reality, there are many statistical measures that can use Oramed Pharmaceuticals historical prices to predict the future Oramed Pharmaceuticals' volatility.| Risk Adjusted Performance | 0.1847 | |||
| Jensen Alpha | 0.6104 | |||
| Total Risk Alpha | 0.4126 | |||
| Sortino Ratio | 0.2623 | |||
| Treynor Ratio | 0.375 |
Oramed Pharmaceuticals February 11, 2026 Technical Indicators
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | 0.1847 | |||
| Market Risk Adjusted Performance | 0.385 | |||
| Mean Deviation | 2.76 | |||
| Semi Deviation | 1.98 | |||
| Downside Deviation | 2.67 | |||
| Coefficient Of Variation | 452.46 | |||
| Standard Deviation | 3.59 | |||
| Variance | 12.87 | |||
| Information Ratio | 0.1952 | |||
| Jensen Alpha | 0.6104 | |||
| Total Risk Alpha | 0.4126 | |||
| Sortino Ratio | 0.2623 | |||
| Treynor Ratio | 0.375 | |||
| Maximum Drawdown | 17.67 | |||
| Value At Risk | (3.76) | |||
| Potential Upside | 6.98 | |||
| Downside Variance | 7.13 | |||
| Semi Variance | 3.91 | |||
| Expected Short fall | (3.75) | |||
| Skewness | 0.7272 | |||
| Kurtosis | 0.1919 |
Oramed Pharmaceuticals Backtested Returns
Oramed Pharmaceuticals appears to be unstable, given 3 months investment horizon. Oramed Pharmaceuticals maintains Sharpe Ratio (i.e., Efficiency) of 0.21, which implies the firm had a 0.21 % return per unit of risk over the last 3 months. By analyzing Oramed Pharmaceuticals' technical indicators, you can evaluate if the expected return of 0.75% is justified by implied risk. Please evaluate Oramed Pharmaceuticals' Semi Deviation of 1.98, coefficient of variation of 452.46, and Risk Adjusted Performance of 0.1847 to confirm if our risk estimates are consistent with your expectations. On a scale of 0 to 100, Oramed Pharmaceuticals holds a performance score of 16. The company holds a Beta of 2.09, which implies a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Oramed Pharmaceuticals will likely underperform. Please check Oramed Pharmaceuticals' maximum drawdown, and the relationship between the information ratio and expected short fall , to make a quick decision on whether Oramed Pharmaceuticals' historical price patterns will revert.
Auto-correlation | 0.77 |
Good predictability
Oramed Pharmaceuticals has good predictability. Overlapping area represents the amount of predictability between Oramed Pharmaceuticals time series from 13th of November 2025 to 28th of December 2025 and 28th of December 2025 to 11th of February 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Oramed Pharmaceuticals price movement. The serial correlation of 0.77 indicates that around 77.0% of current Oramed Pharmaceuticals price fluctuation can be explain by its past prices.
| Correlation Coefficient | 0.77 | |
| Spearman Rank Test | 0.63 | |
| Residual Average | 0.0 | |
| Price Variance | 0.09 |
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
| Competition |
Oramed Accumulated Other Comprehensive Income
Accumulated Other Comprehensive Income |
|
Based on the recorded statements, Oramed Pharmaceuticals reported net income of (19.06 Million). This is 105.58% lower than that of the Pharmaceuticals sector and 127.21% lower than that of the Health Care industry. The net income for all United States stocks is 103.34% higher than that of the company.
Oramed Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Oramed Pharmaceuticals' direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Oramed Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Oramed Pharmaceuticals by comparing valuation metrics of similar companies.Oramed Pharmaceuticals is currently under evaluation in net income category among its peers.
Oramed Pharmaceuticals ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Oramed Pharmaceuticals' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Oramed Pharmaceuticals' managers, analysts, and investors.Environmental | Governance | Social |
Oramed Pharmaceuticals Institutional Holders
Institutional Holdings refers to the ownership stake in Oramed Pharmaceuticals that is held by large financial organizations, pension funds or endowments. Institutions may hold large blocks of Oramed Pharmaceuticals' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Oramed Pharmaceuticals' value.| Shares | Connor Clark & Lunn Inv Mgmt Ltd | 2025-06-30 | 60.4 K | Susquehanna International Group, Llp | 2025-06-30 | 48.4 K | Royal Bank Of Canada | 2025-06-30 | 47.6 K | Squarepoint Ops Llc | 2025-06-30 | 46.1 K | Rbf Llc | 2025-06-30 | 42.9 K | Jane Street Group Llc | 2025-06-30 | 42.4 K | Morgan Stanley - Brokerage Accounts | 2025-06-30 | 32.1 K | Geode Capital Management, Llc | 2025-06-30 | 24.3 K | Pnc Financial Services Group Inc | 2025-06-30 | 23.2 K | Bml Capital Management Llc | 2025-06-30 | 3.1 M | Murchinson Ltd. | 2025-06-30 | 1.8 M |
Oramed Fundamentals
| Return On Equity | 0.24 | ||||
| Return On Asset | -0.0422 | ||||
| Profit Margin | 21.93 % | ||||
| Operating Margin | (6.51) % | ||||
| Current Valuation | 2.7 M | ||||
| Shares Outstanding | 39.8 M | ||||
| Shares Owned By Insiders | 14.60 % | ||||
| Shares Owned By Institutions | 23.20 % | ||||
| Number Of Shares Shorted | 408.59 K | ||||
| Price To Earning | (11.22) X | ||||
| Price To Book | 0.67 X | ||||
| Price To Sales | 67.34 X | ||||
| Gross Profit | 13 K | ||||
| EBITDA | (14.87 M) | ||||
| Net Income | (19.06 M) | ||||
| Cash And Equivalents | 133.91 M | ||||
| Cash Per Share | 3.45 X | ||||
| Total Debt | 372 K | ||||
| Debt To Equity | 0.01 % | ||||
| Current Ratio | 21.01 X | ||||
| Book Value Per Share | 4.98 X | ||||
| Cash Flow From Operations | (8.41 M) | ||||
| Short Ratio | 1.60 X | ||||
| Earnings Per Share | 0.99 X | ||||
| Target Price | 3.25 | ||||
| Beta | 1.31 | ||||
| Market Capitalization | 134.69 M | ||||
| Total Asset | 155.28 M | ||||
| Retained Earnings | (176.62 M) | ||||
| Working Capital | 137.54 M | ||||
| Current Asset | 31 M | ||||
| Current Liabilities | 4 M | ||||
| Annual Yield | 0.07 % | ||||
| Net Asset | 155.28 M |
About Oramed Pharmaceuticals Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Oramed Pharmaceuticals's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Oramed Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Oramed Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Pair Trading with Oramed Pharmaceuticals
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Oramed Pharmaceuticals position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Oramed Pharmaceuticals will appreciate offsetting losses from the drop in the long position's value.Moving together with Oramed Stock
| 0.88 | JNJ | Johnson Johnson Sell-off Trend | PairCorr |
| 0.67 | PFE | Pfizer Inc Aggressive Push | PairCorr |
| 0.89 | LPCN | Lipocine | PairCorr |
Moving against Oramed Stock
| 0.85 | HPQ | HP Inc Aggressive Push | PairCorr |
| 0.73 | MSFT | Microsoft Sell-off Trend | PairCorr |
| 0.53 | BRK-A | Berkshire Hathaway | PairCorr |
| 0.31 | MMM | 3M Company | PairCorr |
The ability to find closely correlated positions to Oramed Pharmaceuticals could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Oramed Pharmaceuticals when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Oramed Pharmaceuticals - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Oramed Pharmaceuticals to buy it.
The correlation of Oramed Pharmaceuticals is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Oramed Pharmaceuticals moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Oramed Pharmaceuticals moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Oramed Pharmaceuticals can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Additional Tools for Oramed Stock Analysis
When running Oramed Pharmaceuticals' price analysis, check to measure Oramed Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Oramed Pharmaceuticals is operating at the current time. Most of Oramed Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Oramed Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Oramed Pharmaceuticals' price. Additionally, you may evaluate how the addition of Oramed Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.